Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total revenue	$ 148,401	$ 145,544	$ 326,767	$ 285,196
Amortization of other intangible assets	12,400	7,900	15,900	24,000
Purchase accounting impact on inventory	2,912		5,781
Restructuring charges	1,499	122	2,961	295
Contingent consideration - fair value adjustments	(17,145)	600	(17,145)	600
Tariff adjustment		(486)		(486)
Operating income (loss)	(12,977)	(4,708)	(40,662)	(5,033)
Interest income	10,394	3,076	21,059	3,111
Interest expense		(1,555)		(2,010)
Loss on extinguishment of debt		(632)		(632)
Other income (expense)	(2,668)	(1,170)	(1,523)	(2,248)
Loss before income taxes	(5,251)	(4,989)	(21,126)	(6,812)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	4,901	1,840	9,070	3,613
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	7,509	6,047	14,882	12,319
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	58,860	53,615	148,520	103,487
Operating income (loss)	(16,404)	5,288	(20,202)	9,679
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	89,541	91,929	178,247	181,709
Operating income (loss)	(4,878)	4,856	(9,490)	12,740
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	148,401	145,544	326,767	285,196
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating income (loss)	(21,282)	10,144	(29,692)	22,419
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense (income)	$ (7,981)	$ 7,329	$ (4,579)	$ 11,711